Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements [Yahoo! Finance]
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed (NASDAQ:OBIO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Orchestra BioMed (NASDAQ:OBIO) had its price target lowered by analysts at Barclays PLC from $12.00 to $11.00. They now have an "overweight" rating on the stock.